Literature DB >> 2333034

Growth of canine distemper virus in cultured astrocytes: relationship to in vivo persistence and disease.

S Pearce-Kelling1, W J Mitchell, B A Summers, M J Appel.   

Abstract

Canine distemper virus (CDV) causes an encephalomyelitis in dogs which varies with the viral strain. The CDV Cornell A75-17 strain produces a delayed, subacute to chronic, demyelinating CNS disease. In contrast, the Snyder Hill (CDV-SH) strain-associated neurological disease is more acute in onset, is usually non-demyelinating and primarily produces lesions in the gray matter. In these studies we describe the effects of these two virulent and one avirulent CDV strain, Rockborn (CDV-RO), on astrocytes in dissociated canine brain cell cultures. In multiple replicate experiments, astrocytes were infected most rapidly by CDV-RO [100% of astrocytes were infected by 14 days post-inoculation (p.i.)]. This strain caused severe cytopathic effect (CPE) and cytolysis. CDV-SH similarly produced a rapid infection of the astrocytes. In contrast, CDV A75-17 infected less than 25% of the astrocyte population during the first 28 days p.i. (+/- 7 days); after 28 days p.i., a rapid rise in astrocyte infection occurred. Both virulent viruses caused astrocytic syncytial formation but did not cause cytolysis of the astrocyte population as was observed with the attenuated virus. Titers of infectious virus, released into the supernatant fluid, reflected the degree of astrocyte infection. Virus released by the cultures late in CDV A75-17 infection showed enhanced ability to infect newly derived astrocytes; in contrast, brain cell passaged CDV-SH did not show increased growth in these cells. These results show that (1) there is a difference in growth rate, CPE and capacity for adaptation of three different CDV strains in astrocytes in vitro, and (2) some aspects of the disease (such as persistence in white matter) produced by the virulent strains in vivo may be related to the course of astrocyte infection observed in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2333034      PMCID: PMC7135698          DOI: 10.1016/0882-4010(90)90009-f

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  22 in total

1.  Encephalitis in dogs produced by distemper virus.

Authors:  J H GILLESPIE; C G RICKARD
Journal:  Am J Vet Res       Date:  1956-01       Impact factor: 1.156

2.  Evidence of oligodendrocyte infection and degeneration in canine distemper encephalomyelitis.

Authors:  W F Blakemore; B A Summers; M G Appel
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

3.  Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method.

Authors:  T H The; T E Feltkamp
Journal:  Immunology       Date:  1970-06       Impact factor: 7.397

4.  A post-vaccinal inclusion body encephalitis in dogs.

Authors:  W J Hartley
Journal:  Vet Pathol       Date:  1974       Impact factor: 2.221

5.  Canine distemper virus does not infect oligodendrocytes in vitro.

Authors:  M Vandevelde; A Zurbriggen; M Dumas; D Palmer
Journal:  J Neurol Sci       Date:  1985-07       Impact factor: 3.181

6.  Canine distemper encephalomyelitis: variation with virus strain.

Authors:  B A Summers; H A Greisen; M J Appel
Journal:  J Comp Pathol       Date:  1984-01       Impact factor: 1.311

7.  Persistence of virulent canine distemper virus in lymphoblastoid cell lines.

Authors:  J M Friedlander; B A Summers; M J Appel
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

8.  Characterization of canine distemper viruses adapted to neural cells and their neurovirulence in mice.

Authors:  Y Yoshikawa; K Yamanouchi; Y Morikawa; M Sakaguchi
Journal:  Microbiol Immunol       Date:  1983       Impact factor: 1.955

9.  Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.

Authors:  K D McCarthy; J de Vellis
Journal:  J Cell Biol       Date:  1980-06       Impact factor: 10.539

10.  In vivo and in vitro models of demyelinating disease. XI. Tropism and differentiation regulate the infectious process of coronaviruses in primary explants of the rat CNS.

Authors:  S Beushausen; S Dales
Journal:  Virology       Date:  1985-02       Impact factor: 3.616

View more
  7 in total

1.  Measles virus-induced disruption of the glial-fibrillary-acidic protein cytoskeleton in an astrocytoma cell line (U-251).

Authors:  W P Duprex; S McQuaid; B K Rima
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Canine distemper virus persistence in the nervous system is associated with noncytolytic selective virus spread.

Authors:  A Zurbriggen; H U Graber; A Wagner; M Vandevelde
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

3.  Studies on canine distemper virus persistence in the central nervous system.

Authors:  C F Müller; R S Fatzer; K Beck; M Vandevelde; A Zurbriggen
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

4.  Signal peptide and helical bundle domains of virulent canine distemper virus fusion protein restrict fusogenicity.

Authors:  Philippe Plattet; Pascal Cherpillod; Dominique Wiener; Ljerka Zipperle; Marc Vandevelde; Riccardo Wittek; Andreas Zurbriggen
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

5.  Use of quantitative real-time RT-PCR to investigate the correlation between viremia and viral shedding of canine distemper virus, and infection outcomes in experimentally infected dogs.

Authors:  Go Sehata; Hiroaki Sato; Toshihiro Ito; Yoshitaka Imaizumi; Taichi Noro; Eiji Oishi
Journal:  J Vet Med Sci       Date:  2015-03-01       Impact factor: 1.267

6.  Virulent and attenuated canine distemper virus infects multiple dog brain cell types in vitro.

Authors:  S Pearce-Kelling; W J Mitchell; B A Summers; M J Appel
Journal:  Glia       Date:  1991       Impact factor: 7.452

Review 7.  Aspects of canine distemper virus and measles virus encephalomyelitis.

Authors:  B A Summers; M J Appel
Journal:  Neuropathol Appl Neurobiol       Date:  1994-12       Impact factor: 8.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.